• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

Target cell-restricted triggering of the CD95 (APO-1/Fas) death receptor with bispecific antibody fragments.

作者信息

Jung G, Grosse-Hovest L, Krammer P H, Rammensee H G

机构信息

Department of Immunology, Institute for Cell Biology, University of Tübingen, Germany.

出版信息

Cancer Res. 2001 Mar 1;61(5):1846-8.

PMID:11280736
Abstract

Like many other cell surface receptors, the CD95 (APO-1/Fas) molecule needs to be cross-linked by its physiological ligand or by immobilized or multimeric antibodies to mediate biological activity, that is, induction of apoptotic cell death. Monomeric CD95 antibodies of the IgG2a or IgG1 subtype block rather than induce apoptosis. We report here that such antibodies, hybridized to a second antibody directed against a different target antigen on the same cell, effectively induce apoptosis of the cells if the expression of the target antigen exceeds a certain threshold level. It appears that this effect is due to bicellular binding of bispecific antibodies resulting in mutual cross-linking of the CD95 death receptor and the target antigen. Using bispecific reagents, it may therefore be possible to restrict the activation of death receptors to a given target site, e.g., a tumor. In general terms, our findings illustrate a principle according to which the triggering of a cell surface receptor may be confined to a given target cell using bispecific reagents with target X cell surface receptor specificity.

摘要

相似文献

1
Target cell-restricted triggering of the CD95 (APO-1/Fas) death receptor with bispecific antibody fragments.
Cancer Res. 2001 Mar 1;61(5):1846-8.
2
Construction of optimized bispecific antibodies for selective activation of the death receptor CD95.用于选择性激活死亡受体CD95的优化双特异性抗体的构建。
Cancer Res. 2008 Feb 15;68(4):1221-7. doi: 10.1158/0008-5472.CAN-07-6175.
3
Construction and characterization of a bispecific anti-CD20 antibody with potent antitumor activity against B-cell lymphoma.构建并鉴定一种具有强抗肿瘤活性的抗 CD20 双特异性抗体,用于治疗 B 细胞淋巴瘤。
Cancer Res. 2010 Aug 1;70(15):6293-302. doi: 10.1158/0008-5472.CAN-10-0009. Epub 2010 Jul 14.
4
A novel bispecific tetravalent antibody fusion protein to target costimulatory activity for T-cell activation to tumor cells overexpressing ErbB2/HER2.一种新型双特异性四价抗体融合蛋白,用于靶向共刺激活性,以激活针对过表达ErbB2/HER2的肿瘤细胞的T细胞。
J Mol Biol. 2005 Mar 11;346(5):1299-311. doi: 10.1016/j.jmb.2004.12.052. Epub 2005 Jan 22.
5
Decreased zeta chain expression and apoptosis in CD3+ peripheral blood T lymphocytes of patients with melanoma.黑色素瘤患者CD3 +外周血T淋巴细胞中ζ链表达降低及细胞凋亡
Clin Cancer Res. 2001 Mar;7(3 Suppl):947s-957s.
6
FAS death domain deletions and cellular FADD-like interleukin 1beta converting enzyme inhibitory protein (long) overexpression: alternative mechanisms for deregulating the extrinsic apoptotic pathway in diffuse large B-cell lymphoma subtypes.FAS死亡结构域缺失与细胞中FADD样白介素1β转化酶抑制蛋白(长型)过表达:弥漫性大B细胞淋巴瘤亚型中外源性凋亡途径失调的替代机制
Clin Cancer Res. 2006 Jun 1;12(11 Pt 1):3265-71. doi: 10.1158/1078-0432.CCR-06-0076.
7
Target cell-restricted apoptosis induction of acute leukemic T cells by a recombinant tumor necrosis factor-related apoptosis-inducing ligand fusion protein with specificity for human CD7.一种对人CD7具有特异性的重组肿瘤坏死因子相关凋亡诱导配体融合蛋白对急性白血病T细胞的靶细胞限制性凋亡诱导作用
Cancer Res. 2005 Apr 15;65(8):3380-8. doi: 10.1158/0008-5472.CAN-04-2756.
8
Ligand-independent redistribution of Fas (CD95) into lipid rafts mediates clonotypic T cell death.Fas(CD95)在不依赖配体的情况下重新分布到脂筏中,介导克隆型T细胞死亡。
Nat Immunol. 2004 Feb;5(2):182-9. doi: 10.1038/ni1024. Epub 2004 Jan 25.
9
Activation-induced apoptosis and cell surface expression of Fas (CD95) ligand are reciprocally regulated by retinoic acid receptor alpha and gamma and involve nur77 in T cells.维甲酸受体α和γ相互调节活化诱导的细胞凋亡及Fas(CD95)配体的细胞表面表达,且这一过程在T细胞中涉及Nur77。
Eur J Immunol. 2001 May;31(5):1382-91. doi: 10.1002/1521-4141(200105)31:5<1382::AID-IMMU1382>3.0.CO;2-Y.
10
Brief cross-linking of Fas/APO-1 (CD95) triggers engulfment of pre-apoptotic target cells.Fas/APO-1(CD95)的短暂交联触发凋亡前期靶细胞的吞噬作用。
FEBS Lett. 2008 Oct 15;582(23-24):3501-8. doi: 10.1016/j.febslet.2008.09.020. Epub 2008 Sep 18.

引用本文的文献

1
IgG-Based Bispecific Anti-CD95 Antibodies for the Treatment of B Cell-Derived Malignancies and Autoimmune Diseases.用于治疗B细胞源性恶性肿瘤和自身免疫性疾病的基于IgG的双特异性抗CD95抗体
Cancers (Basel). 2022 Aug 16;14(16):3941. doi: 10.3390/cancers14163941.
2
Therapeutic approaches targeting CD95L/CD95 signaling in cancer and autoimmune diseases.针对癌症和自身免疫性疾病中 CD95L/CD95 信号的治疗方法。
Cell Death Dis. 2022 Mar 17;13(3):248. doi: 10.1038/s41419-022-04688-x.
3
Subtype-Specific Radiation Response and Therapeutic Effect of FAS Death Receptor Modulation in Human Breast Cancer.
人乳腺癌中FAS死亡受体调节的亚型特异性辐射反应及治疗效果
Radiat Res. 2017 Aug;188(2):169-180. doi: 10.1667/RR14664.1. Epub 2017 Jun 9.
4
Fas Versatile Signaling and Beyond: Pivotal Role of Tyrosine Phosphorylation in Context-Dependent Signaling and Diseases.Fas的多功能信号传导及其他:酪氨酸磷酸化在依赖于背景的信号传导和疾病中的关键作用
Front Immunol. 2016 Oct 17;7:429. doi: 10.3389/fimmu.2016.00429. eCollection 2016.
5
A Recombinant Bispecific CD20×CD95 Antibody With Superior Activity Against Normal and Malignant B-cells.一种对正常和恶性B细胞具有卓越活性的重组双特异性CD20×CD95抗体。
Mol Ther. 2016 Feb;24(2):298-305. doi: 10.1038/mt.2015.209. Epub 2015 Nov 19.
6
T cell-recruiting triplebody 19-3-19 mediates serial lysis of malignant B-lymphoid cells by a single T cell.T细胞招募三体分子19-3-19介导单个T细胞对恶性B淋巴细胞的连续裂解。
Oncotarget. 2014 Aug 15;5(15):6466-83. doi: 10.18632/oncotarget.2238.
7
Death receptors as targets for anti-cancer therapy.作为抗癌治疗靶点的死亡受体
J Cell Mol Med. 2008 Dec;12(6B):2566-85. doi: 10.1111/j.1582-4934.2008.00514.x.